Norfolk Southern has inaugurated its new 'East Edge' double-stack corridor, a decades-in-the-making infrastructure project linking Chicago to New England. The move is set to bolster intermodal capacity in the Northeast and could sharpen the railroad's competitive edge and investor appeal.
As market leadership broadens beyond tech, income-focused investors are turning to high-yield dividend ETFs. Vanguard's suite offers diversified, cost-effective options for building retirement income streams in a changing landscape.
Quince Therapeutics' lead candidate, eDSP, has failed to meet primary and secondary endpoints in its pivotal Phase III NEAT trial for the rare neurological disorder Ataxia-Telangiectasia (A-T), triggering a catastrophic drop in the company's share price.
A partial government shutdown triggers furloughs, the Grammys become a platform for political statements, and nationwide protests over immigration policy unfold amid a severe winter storm's aftermath.
Senior U.S. envoy Steve Witkoff is set to arrive in Jerusalem for meetings with Prime Minister Netanyahu and military leaders, as Washington seeks to navigate escalating regional tensions with Iran and advance efforts to end the Gaza conflict.
The U.S. Food and Drug Administration has issued a complete response letter for Aquestive Therapeutics' oral film drug designed to treat severe allergic reactions, the company announced Monday, delaying a potential new option for millions at risk.
The payments giants Visa and Mastercard reported robust revenue and earnings growth for their latest quarters, though their premium valuations continue to spark investor debate on which offers the superior long-term opportunity.
A coalition of licensed marijuana companies in Missouri has launched a wave of lawsuits against dozens of smoke shops, alleging they are exploiting a legal gray area to sell intoxicating THCA hemp flower, undermining the state's regulated market and creating unfair competition.
Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
A sharp sell-off in gold and silver, alongside falling oil prices, has sparked volatility across global markets at the start of a week packed with major earnings and central bank decisions.
Amid a choppy market landscape in early 2026, value investors are scanning for opportunities. We analyze three companies—Viavi Solutions, Kontoor Brands, and Robert Half—whose current share prices appear significantly disconnected from their estimated intrinsic worth based on cash flow projections.
In Zimbabwe, where formal employment is scarce and medical costs are prohibitive, a stark financial choice is being made: affordable funeral policies are vastly outpacing health insurance, reflecting a cultural prioritization of dignified burials over accessible healthcare.
Precious metals extended their sharp decline following President Trump's nomination for the next Federal Reserve chair, a move markets interpret as locking in higher interest rates and boosting the U.S. dollar's appeal.
Alphabet's self-driving unit Waymo is in advanced talks to secure a massive $16 billion funding round, potentially valuing the company at around $110 billion, as competition in the robotaxi market intensifies.
A new financial analysis suggests shares of the documentary-focused streaming service CuriosityStream may be trading significantly below their estimated intrinsic value, presenting a potential opportunity for investors.
A wave of insider buying at 908 Devices Inc. has caught the market's attention, signaling potential optimism among those who know the company best. While not a guaranteed predictor, such coordinated activity often precedes significant corporate developments.
Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.
A deep dive into Truist Financial's valuation suggests its current share price may not fully reflect its underlying earnings power and book value, presenting a potential opportunity for investors.
A new valuation model suggests Eos Energy Enterprises' stock could be significantly undervalued, presenting a potential opportunity for investors amid a shifting energy policy landscape.
Digital asset funds have recorded a second consecutive week of massive outflows, totaling $1.7 billion, as hawkish Fed signals and geopolitical tensions trigger a defensive shift. While Bitcoin and Ethereum led the retreat, tokenized precious metals emerged as a rare destination for new capital.
